title: Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics.
abstract: BACKGROUND
  Non-adherence to antipsychotic therapy among patients with schizophrenia is a key driver of relapse, which can lead to costly inpatient stays. Long-acting injectables (LAIs) may improve adherence, thus reducing hospitalizations, but inpatient cost reductions need to be balanced against higher drug acquisition costs of LAIs. Real-world evidence is needed to help quantify the economic value of oral atypical antipsychotics compared with LAIs.
  
  
  OBJECTIVE
  The objective of this study was to compare healthcare costs and resource utilization between once-monthly paliperidone palmitate (PP) and oral antipsychotic therapy (OAT) in a population of Medicaid beneficiaries with schizophrenia.
  
  
  METHODS
  A retrospective, observational study was performed using Truven Health MarketScan Medicaid claims data from 2009 to 2012. Marginal structural modeling, a form of weighted repeated measures analysis to control for differences between cohorts and time-varying confounding, was used to estimate monthly costs of care in 2012 US dollars and resource utilization over a 12-month period for patients in each cohort.
  
  
  RESULTS
  While per-month mental-health prescription costs were US$1019 higher in the PP cohort, approximately 55 % of this premium was offset by lower inpatient and outpatient care costs, producing a mean monthly total cost differential of US$434 (95 % CI 298-569,p< 0.0001) for all-cause costs and US$463 (95 % CI 374-552,p< 0.0001) for mental-health-related costs. Use of PP also resulted in a 0.44 and 0.47 reduction in the odds of all-cause and mental-health-related hospitalizations and a 0.09 reduction in the odds of all-cause emergency department visits (p< 0.0001,p< 0.0001, andp= 0.0134, respectively) over the 12-month follow-up period.
  
  
  CONCLUSIONS
  Treatment with long-acting injectable antipsychotics, such as PP, may reduce inpatient and outpatient healthcare services utilization and associated costs. These findings also suggest that patients with schizophrenia taking once-monthly PP may stand a lower risk of hospitalization than patients on OAT.
authors.affiliation: Janssen Scientific Affairs, LLC, 3133 Castle Peak Ave. Superior, Louisville, CO 80027 USA.
authors.forename: Jacqueline A
authors.initials: JA
authors.lastname: Pesa
authors.affiliation: Janssen Scientific Affairs, LLC, 3133 Castle Peak Ave. Superior, Louisville, CO 80027 USA.
authors.forename: Erik
authors.initials: E
authors.lastname: Muser
authors.affiliation: Truven Health Analytics, Cambridge, USA.
authors.forename: Leslie B
authors.initials: LB
authors.lastname: Montejano
authors.affiliation: Truven Health Analytics, Cambridge, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Smith
authors.affiliation: Truven Health Analytics, Cambridge, USA.
authors.forename: Oren I
authors.initials: OI
authors.lastname: Meyers